264 related articles for article (PubMed ID: 12744301)
1. Effect of off-label use of oncology drugs on pharmaceutical costs: the rituximab experience.
Kocs D; Fendrick AM
Am J Manag Care; 2003 May; 9(5):393-400; quiz 401-2. PubMed ID: 12744301
[TBL] [Abstract][Full Text] [Related]
2. [Off label drug use in adult patients treated by anticancer chemotherapy].
Levêque D; Michallat AC; Schaller C; Ranc M
Bull Cancer; 2005 May; 92(5):498-500. PubMed ID: 15932813
[TBL] [Abstract][Full Text] [Related]
3. Medication use in the neonatal intensive care unit: current patterns and off-label use of parenteral medications.
Kumar P; Walker JK; Hurt KM; Bennett KM; Grosshans N; Fotis MA
J Pediatr; 2008 Mar; 152(3):412-5. PubMed ID: 18280851
[TBL] [Abstract][Full Text] [Related]
4. The ethics of off-label use of drugs: oncology pharmacy in Italy.
Bernardi A; Pegoraro R
J Clin Pharm Ther; 2008 Apr; 33(2):95-9. PubMed ID: 18315773
[TBL] [Abstract][Full Text] [Related]
5. Access to anticancer drugs: many evidence-based treatments are off-label and unfunded by the Pharmaceutical Benefits Scheme.
Mellor JD; Van Koeverden P; Yip SW; Thakerar A; Kirsa SW; Michael M
Intern Med J; 2012 Nov; 42(11):1224-9. PubMed ID: 22372936
[TBL] [Abstract][Full Text] [Related]
6. Reimbursement for cancer treatment: coverage of off-label drug indications.
American Society of Clinical Oncology
J Clin Oncol; 2006 Jul; 24(19):3206-8. PubMed ID: 16717290
[TBL] [Abstract][Full Text] [Related]
7. Off-label drug use in hospitalized children.
Shah SS; Hall M; Goodman DM; Feuer P; Sharma V; Fargason C; Hyman D; Jenkins K; White ML; Levy FH; Levin JE; Bertoch D; Slonim AD
Arch Pediatr Adolesc Med; 2007 Mar; 161(3):282-90. PubMed ID: 17339510
[TBL] [Abstract][Full Text] [Related]
8. Satisfaction with pharmacotherapy for approved and off-label indications--a Delphi study.
Kos M; Wertheimer AI; Mrhar A
Ann Pharmacother; 2005 Apr; 39(4):649-54. PubMed ID: 15755789
[TBL] [Abstract][Full Text] [Related]
9. Economics of new oncology drug development.
DiMasi JA; Grabowski HG
J Clin Oncol; 2007 Jan; 25(2):209-16. PubMed ID: 17210942
[TBL] [Abstract][Full Text] [Related]
10. Recombinant human erythropoietin usage in a large academic medical center.
Bilenker JH; Demers R; Porter DL; Wasserstein AG; Peters E; Manaker S
Am J Manag Care; 2002 Aug; 8(8):742-7. PubMed ID: 12212761
[TBL] [Abstract][Full Text] [Related]
11. Lessons learned from independent central review.
Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
[TBL] [Abstract][Full Text] [Related]
12. Market uptake of biologic and small-molecule--targeted oncology drugs in Europe.
Obradovic M; Mrhar A; Kos M
Clin Ther; 2009 Dec; 31(12):2940-52. PubMed ID: 20110034
[TBL] [Abstract][Full Text] [Related]
13. Diffusion into use of exenatide for glucose control in diabetes mellitus: a retrospective cohort study of a new therapy.
Segal JB; Dy SM; Millman EA; Herbert R; Bass EB; Wu A
Clin Ther; 2007 Aug; 29(8):1784-94. PubMed ID: 17919559
[TBL] [Abstract][Full Text] [Related]
14. Use and coverage of novel cancer agents in managed care.
Bailes JS
Semin Oncol; 1994 Dec; 21(6 Suppl 14):34-7. PubMed ID: 7992098
[TBL] [Abstract][Full Text] [Related]
15. [Anticancer drugs use evaluation: limits of the approved labeling].
Debrix I; André T; Flahault A; Kalu O; Gligorov J; Lotz JP; Milleron B; Pene F; Boukari Y; Becker A
Bull Cancer; 2004 May; 91(5):437-43. PubMed ID: 15281283
[TBL] [Abstract][Full Text] [Related]
16. An epidemiological investigation of off-label anticonvulsant drug use in the Georgia Medicaid population.
Chen H; Deshpande AD; Jiang R; Martin BC
Pharmacoepidemiol Drug Saf; 2005 Sep; 14(9):629-38. PubMed ID: 15597329
[TBL] [Abstract][Full Text] [Related]
17. [Off-label use: update and relevance for urology].
Krege S; Rohde D
Aktuelle Urol; 2007 Jul; 38(4):301-4. PubMed ID: 17647167
[TBL] [Abstract][Full Text] [Related]
18. Uses of drugs not described in the package insert (off-label uses).
Committee on Drugs. American Academy of Pediatrics
Pediatrics; 2002 Jul; 110(1 Pt 1):181-3. PubMed ID: 12093968
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the off-label usage of rituximab in a large teaching hospital in New South Wales.
Sharma R; Koller L; Barclay P; Liddle C
Intern Med J; 2007 Aug; 37(8):569-71. PubMed ID: 17640190
[TBL] [Abstract][Full Text] [Related]
20. Adverse drug reactions and off-label prescribing for paediatric outpatients: a one-year survey of spontaneous reports in Sweden.
Ufer M; Kimland E; Bergman U
Pharmacoepidemiol Drug Saf; 2004 Mar; 13(3):147-52. PubMed ID: 15072113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
